Dialysis myelopathy: quadriparesis due to extradural amyloid of 2 microglobulin origin
1988; BMJ; Volume: 296; Issue: 6624 Linguagem: Inglês
10.1136/bmj.296.6624.752
ISSN0959-8138
AutoresTheresa J. Allain, P. E. Stevens, Leslie Bridges, Malcolm Phillips,
Tópico(s)Neurological and metabolic disorders
ResumoMean (SEM) concentrations of growth hormone, insulin, and glucose over 24 hours with each dose regimen.For statistical analysis (Students paired t test) growth hormone and insulin concentrations were log transformed Dose of octreotide (sg thrice daily) Control 100 500 1000Growth hormone (mIU/l): 24 h Profile 40 (18)* 8-5 (3-2)t 3-8 (0-5) 3-1(0 4) 10 h After dose 45 ( 16)* 17-7 (4 0)i 5-2 (0-6) § 2-8 (0 2) Insulin (mU/I): 24 h Profile 33 (7-1)* 17 (3-7)t (3 0) 10-6 (1-5) Glucose (mmol/l):24 h Profile 5 2 (0-3) 5-3 (0 2) 5-5 (0 2) 5-4 (0 2) *Control v 100, 500, and 1000 [tg p<0001.tlO0 v 1000 [tg p<o-o.t100 v 500 ,tg p<005.1500 v 1000 itg p<002.concentration with any of the doses.Growth hormone concentration was within normal limits 10 hours after 1000 ig octreotide but not after 100 or 500 ,g.Daily measurements ofgrowth hormone concentration showed no change on each ofthe three days of each dose regimen.Twenty four hour profiles obtained in the four patients on the last day of the long term study did not differ from those obtained in the acute study at this dose.No patient experienced subjective or objective side effects while taking octreotide.There was no change in blood count, biochemical profile, or thyroxine, cortisol, prolactin, luteinising hormone, follicle stimulating hormone, and sex hormone concentrations at the highest dose.
Referência(s)